Innovent Biologics, Inc.
1801
Pozycja w akcjach
#1160
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou,... Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
Cena akcji
$11.39
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$19.87B
Zmiana (1 dzień)
1.48%
Zmiana (1 rok)
1.94%
Kraj
CN
Handel Innovent Biologics, Inc. (1801)
Kategoria
Healthcare
Marża operacyjna dla Innovent Biologics, Inc. (1801)
Marża operacyjna na dzień October 2026 TTM: 12.02%
Według najnowszych raportów finansowych i ceny akcji Innovent Biologics, Inc., bieżąca marża operacyjna (TTM) wynosi 12.02%. Na koniec 2023 wynosiła -27.06%.
Historia marży operacyjnej dla Innovent Biologics, Inc. od 2016 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 12.02% | -249.88% |
| 2024 | -8.02% | -70.36% |
| 2023 | -27.06% | -60.52% |
| 2022 | -68.54% | 8.26% |
| 2021 | -63.31% | 336.62% |
| 2020 | -14.50% | -90.87% |
| 2019 | -158.76% | -99.16% |
| 2018 | -18,841.75% | 365.63% |
| 2017 | -4,046.48% | 181.67% |
| 2016 | -1,436.60% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 38.59% | -96.79% |
US
|
|
| -149.01% | -112.40% |
US
|
|
| 25.57% | -97.87% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -97.60% |
NL
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.